The molecular gutliver signaling, we substantially revised the manuscript with detailed discussions of key pathways: TLR4/NF-B, MAPK signaling, tight junction regulation, microbial metabolite signaling (e.g., SCFAs), and cytokine cascades
[4] [5] These symptoms typically occur early in treatment or after dose increases and often diminish over time
Boey Yee Cheng, associate director, Ipsos Rare Disease Monitors Drug: Atacicept Company: Vera Therapeutics Indication: IgA nephropathy (IgAN) Stage: Phase III (pre-approval) Background: Veras atacicept is a dual inhibitor of APRIL and BLyS (B lymphocyte stimulator), targeting B-cell survival and IgA production in IgA nephropathy (IgAN), also known as Bergers disease
Its primary intent is to potentially smooth out the drugs effects and mitigate acute side effects that some individuals experience shortly after a single, larger weekly injection
And even if you qualify, prior authorization is not guaranteed
